8-K: Gilead Sciences Announces First Quarter 2025 Financial Results: Product Sales Excluding Veklury Increase 4%

Gilead Sciences reports flat revenue for Q1 2025, but sees growth in HIV and Liver Disease sales offsetting declines in Veklury and Oncology.

Summary

• Gilead Sciences announced its first quarter 2025 financial results, with total revenue remaining flat at $6.7 billion compared to the same period in 2024.
• Product sales excluding Veklury increased by 4% year-over-year to $6.3 billion, driven by higher HIV and Liver Disease sales, which were partially offset by lower Oncology sales.
• Diluted earnings per share (EPS) was $1.04, a significant increase from $(3.34) in Q1 2024, primarily due to the absence of prior year charges related to the CymaBay Therapeutics acquisition and an IPR&D impairment.
• Non-GAAP diluted EPS was $1.81, compared to $(1.32) in the same period last year, also driven by the absence of the prior year IPR&D expense.
• As of March 31, 2025, Gilead had $7.9 billion in cash and cash equivalents, compared to $10.0 billion at the end of 2024.
• The company generated $1.8 billion in operating cash flow, paid dividends of $1.0 billion, and repurchased $730 million of common stock during the quarter.
• Gilead repaid $1.8 billion of Senior Notes in February 2025.
• The company reaffirmed its full-year 2025 product sales guidance of $28.2 billion to $28.6 billion and non-GAAP diluted EPS guidance of $7.70 to $8.10, while narrowing its diluted EPS guidance to $5.65 to $6.05.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While revenue was flat, there was growth in key areas like HIV and Liver Disease. The company is also making progress with its pipeline and returning capital to shareholders. However, the decline in Veklury and Cell Therapy sales, along with the decrease in cash reserves, temper the overall positive outlook.

Positives

• Product sales excluding Veklury increased 4% year-over-year, indicating strength in the core business.
• HIV product sales increased 6%, driven by strong performance of Biktarvy and Descovy.
• Liver Disease portfolio sales increased 3%, reflecting increased demand for PBC, HBV, and HDV products.
• The company generated $1.8 billion in operating cash flow.
• Gilead is returning capital to shareholders through dividends and share repurchases.
• The FDA accepted the New Drug Application for lenacapavir for HIV prevention with priority review.
• Trodelvy plus Keytruda showed positive results in a Phase 3 trial for triple-negative breast cancer.

Negatives

• Total revenue remained flat compared to the same period last year.
• Veklury sales decreased significantly due to lower COVID-19 related hospitalizations.
• Cell Therapy product sales decreased 3%.
• Trodelvy sales decreased 5%, driven by inventory dynamics and lower average realized price.
• Cash and cash equivalents decreased from $10.0 billion at the end of 2024 to $7.9 billion as of March 31, 2025.

Risks

• Uncertainty regarding the amount and timing of Veklury revenues.
• Potential impact of the Inflation Reduction Act on pricing and reimbursement.
• Changes in U.S. regulatory or legislative policies.
• Patent protection and estimated loss of exclusivity for products.
• Unfavorable results from ongoing and additional clinical trials.
• Delays in receiving or maintaining regulatory approvals.
• Potential disruptions to the manufacturing and supply chain.
• Market share and price erosion caused by generic versions of Gilead products.
• Physicians and patients may not see advantages of Gilead products over other therapies.

Future Outlook

Gilead reaffirmed its full-year 2025 product sales guidance of $28.2 billion to $28.6 billion and non-GAAP diluted EPS guidance of $7.70 to $8.10, while narrowing its diluted EPS guidance to $5.65 to $6.05.

Management Comments

• Daniel O'Day, Gilead's Chairman and Chief Executive Officer, stated that Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management.
• He highlighted the 4% growth in the base business, primarily led by Biktarvy, and the positive Phase 3 results for Trodelvy plus pembrolizumab in first-line PD-L1+ metastatic triple-negative breast cancer.
• O'Day expressed optimism about building on the positive momentum throughout the year with the upcoming PDUFA date for lenacapavir for HIV prevention and continued progress across the diverse pipeline.

Industry Context

Gilead's focus on HIV, liver diseases, and oncology aligns with major trends in the biopharmaceutical industry. The growth in HIV sales, particularly Biktarvy, reflects the ongoing demand for effective HIV treatments. The expansion into oncology, including the development of Trodelvy, positions Gilead to capitalize on the growing market for cancer therapies. The company's strategic partnerships, such as the one with LEO Pharma, demonstrate a commitment to expanding its portfolio and capabilities.

Comparison to Industry Standards

• Gilead's performance can be compared to other major biopharmaceutical companies such as Johnson & Johnson, Pfizer, and Merck.
• Gilead's HIV franchise, led by Biktarvy, competes with products like Dovato from ViiV Healthcare (a joint venture between GSK, Pfizer, and Shionogi).
• In the oncology space, Gilead's Trodelvy competes with therapies from companies like AstraZeneca and Roche.
• Gilead's R&D spending as a percentage of revenue is in line with industry averages for large pharmaceutical companies.
• The company's focus on non-GAAP financial measures is a common practice in the industry to provide investors with a clearer picture of underlying business performance.

Stakeholder Impact

• Shareholders will benefit from the dividend payment and share repurchase program.
• Patients may benefit from the potential approval of new therapies like lenacapavir and the positive results from the Trodelvy plus Keytruda trial.
• Employees are likely to be impacted by the company's strategic priorities and financial performance.
• The company's suppliers and partners may be affected by changes in its product portfolio and R&D activities.

Next Steps

• The FDA is expected to make a decision on the New Drug Application for twice-yearly lenacapavir for HIV prevention by June 19, 2025.
• Gilead plans to launch a Phase 3 study for once-yearly lenacapavir for HIV prevention in the second half of 2025.
• The company will continue to progress its diverse pipeline and commercialize its products.

Key Dates

Keywords

Gilead Sciences, Financial Results, Q1 2025, Revenue, EPS, HIV, Liver Disease, Oncology, Veklury, Biktarvy, Trodelvy, Lenacapavir, Clinical Trials, Pharmaceuticals